Filing Summary
Business Context and Reporting Period
Soaring Eagle Acquisition Corp. filed this Form 8-K on September 1, 2021, regarding its planned business combination with Ginkgo Bioworks, Inc. The filing is not a financial results report and does not provide a reporting-period income statement or balance sheet.
- Soaring Eagle intends to voluntarily delist its Class A ordinary shares and warrants from Nasdaq after completion of the transaction.
- Following the combination, the company is expected to reincorporate in Delaware and change its name to Ginkgo Bioworks Holdings, Inc.
- The post-combination securities were expected to trade on the New York Stock Exchange under “DNA” for Class A common stock and “DNA.WS” for warrants, beginning the day after closing.
Financial Metrics and Capital Structure
The filing does not provide clear values for revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
The filing states that completion of the transaction is subject to, among other conditions, maintaining a minimum trust account amount following potential shareholder redemptions.
Material Changes Versus the Prior Comparable Period
No period-over-period financial comparison is provided. The principal disclosed change is the planned transition from Soaring Eagle’s Nasdaq-listed securities to the anticipated NYSE listing of Ginkgo Bioworks Holdings, Inc. securities upon closing of the business combination.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no quantitative financial guidance. Forward-looking statements relate primarily to the proposed transaction and the future combined company.
- The transaction may not close on time or at all, or may not close before Soaring Eagle’s business combination deadline.
- Closing depends on shareholder approval, satisfaction of the minimum trust-account condition, regulatory approvals, and other transaction conditions.
- Potential risks include transaction termination, litigation, employee-retention challenges, disruption to Ginkgo’s business relationships, and difficulty implementing business plans after closing.
- Other cited risks include changes in regulation, competitive conditions, capital structure, security-price volatility, and downturns in demand for synthetic-biology products.
- The registration statement was declared effective by the SEC on August 11, 2021, and the definitive proxy statement/prospectus had been mailed to shareholders as of August 10, 2021.
Key Facts for Investor Verification
- Verify whether the business combination closed and the conditions to closing were satisfied.
- Verify the final amount remaining in the trust account after shareholder redemptions.
- Verify the actual NYSE listing date, ticker symbols, and security terms.
- Review the definitive proxy statement/prospectus and related SEC filings for transaction consideration, dilution, pro forma capitalization, and Ginkgo’s financial statements.
- Review the transaction risk factors, including regulatory approvals, litigation, business-combination deadline requirements, and demand risks affecting synthetic biology.